Skip to main content
SpringerLink
Log in

Diabetes

Quantifying genetic susceptibility in T1DM — implications for diagnosis after age 30

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Treatment of type 1 diabetes mellitus (T1DM) for individuals over the age of 30 years is often delayed. A recent large-scale population analysis used a genetic risk score to define T1DM in the first six decades of life, providing specific insights applicable to those >30 years of age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thomas, N. J. et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(17)30362-5 (2017).

    Article  Google Scholar 

  2. Patel, K. A. Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. Diabetes 65, 2094–2099 (2016).

    Article  CAS  Google Scholar 

  3. Bingley, P. J. Clinical applications of diabetes antibody testing. J. Clin. Endocrinol. Metab. 95, 25–33 (2010).

    Article  CAS  Google Scholar 

  4. DuBose, S. N. et al. Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. J. Pediatr. 167, 627–632 (2015).

    Article  Google Scholar 

  5. Douek, I. F. et al. Diabetes in the parents of children with type I diabetes. Diabetologia 45, 495–501 (2002).

    Article  CAS  Google Scholar 

  6. Järvelä, I. Y. et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 29, 607–612 (2006).

    Article  Google Scholar 

  7. Lamberts, L. E. et al. Immune-mediated diseases in primary sclerosing cholangitis. Dig. Liver Dis. 43, 802–806 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Everett Meyer is at the Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford; and the Stanford Diabetes Research Center, Stanford University, Stanford.,

    Everett Meyer

  2. and the Stanford Diabetes Research Center, Stanford University, Stanford.,

    Everett Meyer

  3. David M. Maahs is at the Division of Endocrinology, Department of Pediatrics, Stanford University, Stanford, CA, USA; and the Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.,

    David M. Maahs

  4. and the Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.,

    David M. Maahs

Authors
  1. Everett Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Maahs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Maahs.

Ethics declarations

Competing interests

E.H.M. is funded by the NIH (including 1P30DK116074), JDRF Career Development Award and the Helmsley Charitable Trust. He has no conflicts regarding this topic, but is an adviser and equity holder in GigaGen and Triursus Therapeutics. He also is on an advisory board for Incyte. D.M.M. is funded by the NIH (including 1P30DK116074), JDRF, NSF and the Helmsley Charitable Trust. He has no conflicts regarding this topic, but is on an advisory board for Insulet, has consulted for Abbott Diabetes Care and the Helmsley Charitable Trust, and his institution has received research support or materials from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Type Zero and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meyer, E., Maahs, D. Quantifying genetic susceptibility in T1DM — implications for diagnosis after age 30. Nat Rev Endocrinol 14, 134–135 (2018). https://doi.org/10.1038/nrendo.2018.7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2018.7

  • Springer Nature Limited

Search

Navigation